Phase II Study of IL-11 (Neumega) in Von Willebrand Disease
NCT00151125
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Males and females 18 years of age or older
- Confirmed VWD by 2 of 4 VWD coagulation tests abnormal
- A past bleeding history
- No hormone, oral contraceptive, estrogen use in past 8 weeks
- Willingness to have blood drawn
- Willingness to sign informed consent
- Presence of other bleeding disorder, e.g. acquired VWD, thrombocytopenia
- Use of estrogens, hormones, oral contraceptives in past 8 weeks
- Use of immunomodulatory or experimental drugs or diuretics
- Pregnant or lactating women
- Past cardiac disease, congestive failure, arrhythmia (e.g. atrial fibrillation, atrial
flutter), hypertension, MI, stroke, or thrombosis
- Past allergic reaction to Neumega or DDAVP
- Surgery within the past 8 weeks
- Inability to comply with study protocol requirements
- Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin, or NSAIDs
- Treatment with DDAVP, cryoprecipitate, whole blood, plasma, and plasma derivatives
containing FVIII, VWF within 5 days of study
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Phase II Study of IL-11 (Neumega) in Von Willebrand Disease | |||
Official Title ICMJE | Phase II Comparison Study of Hemostatic Efficacy of Escalating Doses of Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease | |||
Brief Summary | This study is testing the use of rhIL-11 (recombinant interleukin 11, Neumega) in individuals with Von Willebrand disease. The purpose is to evaluate:
| |||
Detailed Description | This is a prospective, single center, open-label, escalating dose Phase II comparison study of interleukin-11 (rhIL-11, Neumega) in subjects with type 1 Von Willebrand Disease (VWD). The purpose is to establish the clinical safety and hemostatic efficacy of rhIL-11 in individuals with type 1 Von Willebrand disease. Study subjects will include the following subjects:
A total of 10-16 subjects are anticipated to be enrolled and complete the study. The specific aims of the study are:
Efficacy will be based on the number and percent increase of VWD-related coagulation tests into the normal range, or at least to 2-3 times baseline. Safety will be based on the number and frequency of adverse reactions, including fever, headache, fatigue, arthralgias, myalgias, fluid retention, and edema. The study will last up to 4 weeks per subject, and for 24 months for the entire study. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Von Willebrand Disease | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 12 | |||
Original Enrollment ICMJE | 9 | |||
Actual Study Completion Date ICMJE | December 2007 | |||
Actual Primary Completion Date | December 2007 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00151125 | |||
Other Study ID Numbers ICMJE | 0403006 0403006 ( Other Identifier: protocol id ) | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Margaret Ragni, University of Pittsburgh | |||
Study Sponsor ICMJE | University of Pittsburgh | |||
Collaborators ICMJE |
| |||
Investigators ICMJE |
| |||
PRS Account | University of Pittsburgh | |||
Verification Date | May 2016 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |